Public Data Commons

CDC is collaborating with the National Institutes of Health [NIH], the Food and Drug Administration [FDA], Vitalant Research Institute [VRI], Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 [the virus that causes COVID-19] and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike [anti-S] antibodies but only infection results in production of anti-nucleocapsid [anti-N] antibodies. Combined seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both. It estimates the proportion of the population with some presumed protection against infection with the virus that causes COVID-19. The term “combined seroprevalence” refers to the combined infection- and vaccination-induced SARS-CoV-2 seroprevalences. This is the population that has anti-S antibodies, regardless of the presence of anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html